On 10 March, Silicon Valley Bank (SVB), a popular bank with venture capital (VC)-backed technology and biotech firms, collapsed. Shockwaves spread across biotech companies, the banking sector and beyond. SVB was already in trouble: the tough fundraising environment for biotech and tech firms meant SVB’s deposits had fallen, while rising interest rates were wreaking havoc with its investments. When those challenges became public, SVB’s shares fell and anxious depositors, including VC firms, began pulling their cash. What resulted was one of the fastest, and largest, bank runs in history. It spread to other regional banks — Signature Bank failed, and San Francisco-based First Republic Bank is still on the rocks — and then to a much bigger one, Credit Suisse.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
214,86 € per year
only 17,91 € per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
About this article
Cite this article
Silicon Valley Bank collapse sends shivers down biotech spines.
Nat Biotechnol 41, 437 (2023). https://doi.org/10.1038/s41587-023-01762-3